Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12269.165 | 0.0508 | -0.9861 | 0.6001 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12269.165 | 0.0637 | -0.9797 | 0.6001 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12098.158 | 0.9308 | 0.8785 | 1.1438 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12098.158 | 1.0299 | 1.0523 | 1.1438 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12098.158 | 0.8189 | 0.6795 | 1.1438 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12098.158 | 0.6425 | 0.3585 | 1.1438 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12098.158 | 0.3504 | -0.2004 | 1.1438 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12098.158 | 0.3400 | -0.2213 | 1.1438 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12098.158 | 0.3056 | -0.2905 | 1.1438 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12098.158 | 0.1335 | -0.6562 | 1.1438 | |
| SUM225CWN | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12098.158 | 0.0050 | -0.9807 | 1.1438 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11058.158 | 0.8812 | 0.8832 | 2.1018 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11058.158 | 0.9594 | 0.9609 | 2.1018 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11058.158 | 0.9140 | 0.9162 | 2.1018 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11058.158 | 0.8601 | 0.8616 | 2.1018 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11058.158 | 0.7302 | 0.7221 | 2.1018 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11058.158 | 0.6962 | 0.6835 | 2.1018 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11058.158 | 0.5652 | 0.5245 | 2.1018 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11058.158 | 0.0484 | -0.5266 | 2.1018 | |
| SUM229PE | TNBC | - | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11058.158 | 0.0072 | -0.8088 | 2.1018 | |
| SUM52PE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11852.158 | 0.9754 | 0.9626 | 1.3172 | |
| SUM52PE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11852.158 | 1.1471 | 1.2196 | 1.3172 | |
| SUM52PE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11852.158 | 1.0129 | 1.0196 | 1.3172 | |
| SUM52PE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11852.158 | 1.0536 | 1.0809 | 1.3172 | |
| SUM52PE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11852.158 | 1.0032 | 1.0048 | 1.3172 |